source
- Biopharma layoffs rise YoY in October but overall trend points down for 2026October marked the first time this year that both the number of biotech and pharma firms announcing workforce cuts and the total employees affected rose compared with 2025. Three additional employ…
- Neurosterix secures $105M Series B to launch phase 2 schizophrenia trialAddex Therapeutics' spinout Neurosterix announced a $105 million Series B financing to fund its upcoming phase 2 trial of NTX-253 for schizophrenia. The round was led by a syndicate of leading lif…